Hilary Clinton to Deliver Keynote at BIO International Convention - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Hilary Clinton to Deliver Keynote at BIO International Convention



Former Secretary of State Hillary Rodham Clinton will deliver a keynote address at the 2014 BIO International Convention in San Diego. The keynote luncheon will take place on Wednesday, June 25 from 12:00 to 1:30 pm PDT. The BIO International Convention offers networking and partnering opportunities and provides insights on major trends affecting the industry. Hillary Rodham Clinton served as the 67th Secretary of State from 2009 until 2013, after nearly four decades in public service.

The keynote session is sponsored by Genentech, and is open to Convention registrants with Convention Access and Convention Access & Partnering badges only.

Source: BIO International Convention

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here